Rivoceranib

Refractory Hematologic Cancer

Zhengzhou UniversitySmall moleculePhase 4 / ApprovedDormant

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

6 Active assets in the Refractory Hematologic Cancer cohort.

Asset / Sponsor	Phase	Rating
Humanized, Dual-Affinity Re-Targeting, Or (Dart), Molecule That Recognizes Both Cd123 And Cd3 City of Hope Medical Center	Phase 2	CCC
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) The First Affiliated Hospital of Xiamen University	Phase 2	CCC
Gm-Csf The First Affiliated Hospital of Xiamen University	Phase 2	CCC
LENALIDOMIDE The First Affiliated Hospital of Xiamen University	Phase 2	CCC
Emavusertib Curis, Inc.	Phase 1/2	CCC